menu
    • menu
    [{"orgOrder":0,"company":"LFB","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"LFB \/ HEMA Biologics","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ HEMA Biologics"},{"orgOrder":0,"company":"LFB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Beta","moa":"Factor VII","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ Not Applicable"},{"orgOrder":0,"company":"LFB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Beta","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by LFB

    Menu

    LFB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LFB

                            France arrow
                            CPhI India 2024
                            Not Confirmed

                            LFB

                            France arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eptacog Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union

                            Details : Cevenfacta (eptacog beta), a new recombinant coagulation Factor VIIa for treatment of bleeding episodes and for prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents with haemophilia A or B with inhibitors.

                            Brand Name : Cevenfacta

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 25, 2022

                            Lead Product(s) : Eptacog Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LFB

                            France arrow
                            CPhI India 2024
                            Not Confirmed

                            LFB

                            France arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eptacog Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CHMP Recommends Cevenfacta to Control Bleeding Episodes in Patients With Congenital Haemophilia

                            Details : Positive opinions by CHMP were issued as a recommendation for marketing authorization was adopted for Cevenfacta (eptacog beta (activated)). Although FDA has approved SEVENFACT as first bypassing agent in over 20 years for patient with hemophilia A or B ...

                            Brand Name : Cevenfacta

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 20, 2022

                            Lead Product(s) : Eptacog Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LFB

                            France arrow
                            CPhI India 2024
                            Not Confirmed

                            LFB

                            France arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eptacog Alfa

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : HEMA Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LFB Announces FDA Approval of SEVENFACT for the Treatment of Adults and Adolescents with Hemophilia A or B wit...

                            Details : An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.

                            Brand Name : Sevenfact

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 06, 2020

                            Lead Product(s) : Eptacog Alfa

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : HEMA Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth